Risk-Based Monitoring in U.S. Clinical Trials: FDA Guidance and Best Practices
Risk-Based Monitoring in U.S. Clinical Trials: FDA Guidance and Best Practices Implementing Risk-Based Monitoring in U.S. Clinical Trials: Regulatory Insights and Case Studies Introduction Risk-Based Monitoring (RBM) has transformed the landscape of clinical trial oversight in the United States, shifting away from 100% on-site source data verification toward a more data-driven, centralized, and adaptive approach….
Read More “Risk-Based Monitoring in U.S. Clinical Trials: FDA Guidance and Best Practices” »